Study Drug Once Daily Dosing Versus Placebo in Patients with Major Depression and Pain

Study Drug Versus Placebo in Generalized Anxiety Disorder. A Randomized Double-Blind Placebo- and Buspirone-Controlled Fixed-Dose Parallel Group Multicenter Study of 10 Weeks (Including a 2-week Single-Blind Placebo Period)

A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy of Study Drug in the Treatment of Premenstrual Dysphoric Disorder (PMDD)

Study Drug plus Study Drug in Combination for Treatment-Resistant Depression without Psychotic Features

A Prospective Multi-Center Open-Label Study of Study Drug in the Management of Patients with Schizophrenia or Schizoaffective Disorder in General Psychiatric Practice

A Phase III Randomized Double-Blind Placebo-Controlled Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of a Modified Release Formulation of Study Drug in Adult Patients with Primary Insomnia

Study Drug in the Treatment of Generalized Anxiety Disorder. An Open Multicenter Safety Study of 5 Months, Including a 1-Month Drug Free Follow-Up Period. Follow Up to GAD Study

An 8-week Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi Center, Fixed Dose Study Comparing the Efficacy and Safety of Study Drug or Study Drug to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder